CN114099516A - 一种动物用复方氨基酸溶液及其制备方法和应用 - Google Patents
一种动物用复方氨基酸溶液及其制备方法和应用 Download PDFInfo
- Publication number
- CN114099516A CN114099516A CN202010905082.XA CN202010905082A CN114099516A CN 114099516 A CN114099516 A CN 114099516A CN 202010905082 A CN202010905082 A CN 202010905082A CN 114099516 A CN114099516 A CN 114099516A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- animals
- parts
- acid solution
- compound amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 113
- -1 Compound amino acid Chemical class 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 40
- 239000011720 vitamin B Substances 0.000 claims abstract description 22
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 22
- 238000001914 filtration Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 5
- 229940024606 amino acid Drugs 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 10
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 239000003651 drinking water Substances 0.000 claims description 7
- 235000020188 drinking water Nutrition 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 4
- 239000008139 complexing agent Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- 239000011716 vitamin B2 Substances 0.000 claims description 4
- 239000011708 vitamin B3 Substances 0.000 claims description 4
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 abstract description 27
- 235000013343 vitamin Nutrition 0.000 abstract description 27
- 239000011782 vitamin Substances 0.000 abstract description 27
- 229940088594 vitamin Drugs 0.000 abstract description 27
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 22
- 230000007812 deficiency Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 89
- 239000000243 solution Substances 0.000 description 68
- 238000012360 testing method Methods 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 8
- 229930003270 Vitamin B Natural products 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 208000000412 Avitaminosis Diseases 0.000 description 5
- 206010021135 Hypovitaminosis Diseases 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 208000030401 vitamin deficiency disease Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000026500 emaciation Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000021243 milk fat Nutrition 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 230000017448 oviposition Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- 241001008148 Aster indicus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000270878 Hyla Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
Abstract
本发明属于畜牧兽医技术领域,公开了一种动物用复方氨基酸溶液及其制备方法和应用,是取辅料、9种氨基酸和B族维生素在水中溶解后,再加入色氨酸溶解,然后通过调pH值、定容、过滤等步骤制得;所得溶液用于改善动物机体营养缺失,适合添加至水中,饲喂动物。本发明通过添加合适比例的氨基酸和维生素,利用维生素促进氨基酸更好吸收,同时利用氨基酸促进维生素发挥更大的药用价值,从而更好的补充动物机体营养,提高动物代谢水平,加速血流运转,促进身体恢复,提高动物的生产性能,解决动物机体营养缺失的问题。
Description
技术领域
本发明属于畜牧兽医技术领域,涉及一种复方氨基酸溶液及其制备方法,具体地说是一种动物用复方氨基酸溶液及其制备方法和应用。
背景技术
目前用于增强动物体能的补充液主要使用葡萄糖溶液、氯化钠溶液和葡萄糖氯化钠溶液,能够调节机体内电解质的平衡,但无法改善动物机体营养缺失的状况,也无法补充动物机体内所需的氨基酸和维生素。氨基酸和维生素作为动物体内非常重要营养素,对动物体生长发育有着深远影响。若动物体内缺乏氨基酸和维生素,会表现出发育不良、代谢缓慢、骨骼松软、体弱多病、生长迟缓等症状,还会进一步影响营养物质的吸收,严重时还会造成肾脏受损、停止生长。动物在生病期间会出现体质虚弱、自身合成代谢能力减弱,若不及时补充足够的氨基酸和维生素,也可能引发一系列疾病,如食欲减退、体重减少、呕吐、严重腹泻等。
发明内容
本发明的目的,是要提供一种动物用复方氨基酸溶液,以解决动物机体营养缺失的问题;
本发明的另一个目的,是要提供上述一种动物用复方氨基酸溶液的制备方法;
本发明还有一个目的,是要提供上述一种动物用复方氨基酸溶液的应用。
为了实现上述目的,本发明采用的技术方案是:
一种动物用复方氨基酸溶液,制成每1000体积份所述动物用复方氨基酸溶液的有效成分的原料,以重量份数计包括:
①由盐酸精氨酸0.80~10.00份、盐酸组氨酸0.60~6.50份、亮氨酸2.00~16.00份、异亮氨酸0.40~14.00份、赖氨酸0.90~13.00份、苯丙氨酸1.00~16.50份、苏氨酸0.60~6.80份、缬氨酸0.40~12.90份和甘氨酸0.90~20.00份组成的组合氨基酸;
②色氨酸0.18~4.80份;
③由维生素B1 1.00~4.00份、维生素B2 2.00~8.00份、维生素B3 10.00~30.00份和维生素B6 2.00~10.00份组成的B族维生素;
④由抗氧剂0.50~1.00份、络合剂0.10~0.30份和防腐剂2.00~10.00份组成的辅料;
⑤余量为水;
其中,重量份数与体积份数的比例关系为1kg:1L。
作为一种限定,所述抗氧剂为亚硫酸氢钠、硫脲或焦亚硫酸钠。
作为另一种限定,所述络合剂为乙二胺四乙酸二钠、酒石酸或柠檬酸。
作为第三种限定,所述防腐剂为苯甲酸钠、尼泊金乙酯钠或尼泊金丙酯钠。
本发明还提供了上述一种动物用复方氨基酸溶液的制备方法,包括依次进行的以下步骤:
1)取辅料加至足够量的纯化水(一般为所得所述动物用复方氨基酸溶液总体积的60~80%)中,80~100℃充分溶解后,再加入组合氨基酸和B族维生素,80~100℃充分溶解,得溶液X;
2)溶液X降温至70℃以下(以60~70℃为佳),加入色氨酸,维持在70℃以下(以60~70℃为佳)充分溶解后,降温至30℃以下,调节pH值,用纯化水定容,过滤,即得所述一种动物用复方氨基酸溶液。
作为一种限定,步骤2)中,调节pH值至4.2~6.8。
作为第二种限定,所述过滤分为粗滤和精滤;
纯化水是煮沸30~40min制得。
作为第三种限定,所述精滤是利用微孔滤膜进行过滤除菌。
本发明也提供了上述一种动物用复方氨基酸溶液的应用,所述一种动物用复方氨基酸溶液用于改善动物机体营养缺失。
作为一种限定,所述一种动物用复方氨基酸溶液添加至饮水中,用于饲喂动物。
由于采用了上述技术方案,本发明与现有技术相比,所取得的技术进步在于:
本发明通过大量实验得到了应用于动物的合适配比的一种动物用复方氨基酸溶液。动物机体内氨基酸与维生素的作用是相辅相成的,本发明通过添加合适比例的氨基酸和维生素,利用维生素促进氨基酸更好吸收,同时利用氨基酸促进维生素发挥更大的药用价值,从而更好的补充动物机体营养,提高动物代谢水平,加速血流运转,促进身体恢复,提高动物的生产性能。本发明的一种动物用复方氨基酸溶液还能够提高饲料利用率,改善料肉比,促进蛋白质的合成,提高机体免疫力和抗氧化能力,降低死亡率。本发明的一种动物用复方氨基酸溶液也可以提高肝脏能力,保肝护肝,减轻机体在代谢过程中产生的毒性代谢产物对组织的毒性作用;
缬氨酸、亮氨酸及异亮氨酸均为支链氨基酸,进入动物体内能够纠正血浆中支链氨基酸和芳香氨基酸失衡,具有调节能量底物、糖元异生底物和肌蛋白的作用;缬氨酸、亮氨酸及异亮氨酸还能在外周被氧化为能源,在不增加肝脏负担的情况下,提高能量的摄入;缬氨酸、亮氨酸及异亮氨酸还可以作为糖元异生的底物,在体内氧化与丙氨酸合成间有一个循环代谢机制,产生较多的热量,每克分子的缬氨酸、亮氨酸、异亮氨酸分别产生32、42、43克分子的ATP,能够为机体提供大量的能量。盐酸精氨酸在动物体内参与鸟氨酸循环,促进尿素的形成,使动物体内产生的氨,经鸟氨酸循环变成无毒的尿素,随尿液排出,从而降低血氨浓度。各氨基酸还可以进入组织细胞,参与蛋白质的合成代谢,获得正氮平衡,并生成酶类、激素、抗体、结构蛋白,促进组织愈合,恢复正常生理功能。
维生素B1是B族维生素之一,是糖代谢的重要辅助因子,在醛基和糖基的主动运输中起辅酶作用,在神经传导和神经元传导中起辅助作用。维生素B2(核黄素)在动物体内代谢过程中起辅酶的作用,有助于维持动物的健康。当缺乏维生素B2时,动物体内的碳水化合物、脂肪和蛋白质等物质就不能被转化成能量来维持身体正常功能。维生素B3(烟酰胺)在动物体内有多种光保护作用,它能增强动物体的DNA修复,减少紫外线辐射对动物体皮肤免疫反应的作用,调节炎症细胞产生的皮肤屏障功能,恢复因紫外线照射后的细胞损伤。B6是动物体内某些辅酶的组成成分,参与多种代谢反应,尤其是和氨基酸代谢有密切关系。B族维生素是所有动物体组织必不可少的营养素,均是辅酶,参与体内蛋白质、糖和脂肪的代谢,是食物释放能量的关键。各种维生素B的作用相辅相成,单独摄入某种维生素B后,由于细胞活动增加,从而对其它B族维生素的需求跟着增加,即所谓的“木桶原理”,这也称为维生素B的融合作用,具有增加食欲、维持神经功能、促进生长发育,因此合理配比B族维生素中的各组分至关重要。而氨基酸是蛋白质合成的主要来源,直接关系到动物体能以及健康情况,而B族维生素直接影响氨基酸的吸收利用率,因此,合理配比氨基酸和B族维生素中各组分直接影响动物体对氨基酸和B族维生素的吸收利用,进而影响动物体能及健康状况,同时补充氨基酸和B族维生素在动物体养殖过程中具有重要意义。
本发明将pH值调节至4.2~6.8,从而保证氨基酸和维生素的稳定性,进一步保障氨基酸和维生素的合理配比;采用微孔滤膜过滤除菌,在保障氨基酸和维生素稳定性的同时,去除溶液中的微生物,保障一种动物用复方氨基酸溶液的质量;
本发明的制备方法简单,制备的一种动物用复方氨基酸溶液安全可控;
进一步地,本发明的一种动物用复方氨基酸溶液在生产、使用过程中,能够节约生产、包装、运输成本,方便兽医使用;
本发明原料来源广、成本低廉,能够给养殖企业带来良好的经济效益。
本发明的一种动物用复方氨基酸溶液适合添加至水中,饲喂动物,以改善动物机体营养缺失。
具体实施方式
下面通过具体实施例对本发明做进一步详细说明,应当理解所描述的实施例仅用于解释本发明,并不限定本发明。
实施例1一种动物用复方氨基酸溶液的制备方法
本实施例制备1000L一种动物用复方氨基酸溶液,包括依次进行的以下步骤:
1)称取0.8kg盐酸精氨酸、0.65kg盐酸组氨酸、3.49kg亮氨酸、0.52kg异亮氨酸、1.55kg赖氨酸、1.96kg苯丙氨酸、0.80kg苏氨酸、2.56kg缬氨酸和3.48kg甘氨酸,作为A组氨基酸备用;
称取2.31kg维生素B1、4.52kg维生素B2、25kg维生素B3和6.84kg维生素B6,作为B族维生素备用;
纯化水经煮沸30min,备用;
取800L(一般取600~800L,本实施例取800L)纯化水加入配制容器中,维持80℃,加入0.1kg乙二胺四乙酸二钠、0.5kg硫脲和5.0kg尼泊金乙酯钠,维持80℃搅拌至充分溶解后,再加入38.67kg的B族维生素,维持80℃搅拌至充分溶解,然后加入14.81kg的A组氨基酸,维持80℃搅拌至充分溶解,得溶液X1。
亚硫酸氢钠、硫脲和焦亚硫酸钠均具有防止氨基酸和维生素氧化的作用,本实施例使用硫脲作为抗氧化剂,在加入各氨基酸和维生素之前加入,能够有效防止氨基酸和维生素在溶解过程中发生氧化反应;
乙二胺四乙酸二钠能够与原料中所带入的金属离子发生螯合作用,在加入氨基酸和维生素之前加入,有效避免金属离子对氨基酸和维生素的催化氧化作用。
氨基酸和维生素的溶解时间随温度的升高而缩短,温度在80℃以上时,溶解速度最快,而高于80℃时,大部分氨基酸及维生素的溶解度和溶解速度均不再发生明显变化。综合考虑含量与溶解时间等因素,在80~100℃之间分步加入A组氨基酸和B族维生素进行溶解。
2)溶液X1降温至70℃,加入0.48kg色氨酸,维持70℃搅拌至充分溶解后,降温至30℃,使用1mol/L氢氧化钠溶液调节pH值至4.5,然后再加入煮沸后的纯化水定容至1000L,经1μm的滤芯进行粗滤、0.2μm的微孔滤膜进行精滤除去杂质及微生物,即得一种动物用复方氨基酸溶液。
一种动物用复方氨基酸溶液进行灌装,灌装完成后经灯检合格,制得独立包装的一种动物用复方氨基酸溶液(标记为N1)。
由于色氨酸稳定性不太高,随着温度升高,含量反而会大幅度下降,经实验验证,色氨酸在60~70℃时溶液内的含量较高。将色氨酸控制在60~70℃溶解,有效减少色氨酸溶解过程中的氧化作用。
在制备一种动物用复方氨基酸溶液过程中,将pH值控制在4.2~6.8,能够保持溶液中的氨基酸和维生素含量的稳定性。
0.2μm或0.22μm的微孔滤膜可以起到除菌的作用,保证所得溶液中的微生物限度符合要求,增加溶液质量的稳定性。
所得的一种动物用复方氨基酸溶液适合添加至饮水中,饲喂动物,以改善动物机体营养缺失。
实施例2~6一种动物用复方氨基酸溶液的制备方法
实施例2~6分别为一种动物用复方氨基酸溶液的制备方法,它们的步骤与实施例1基本相同,不同之处仅在于原料用量及工艺参数的不同,具体详见表1:
表1实施例2~6中各项工艺参数一览表
实施例2~6其它部分的内容,与实施例1相同。
实施例7一种动物用复方氨基酸溶液的含量测定结果
根据国家食品药品监督管理总局质量标准WS1-(X-077)-2006Z,氨基酸和维生素相应的标示量应控制在90.0~110.0%,标示量计算是根据所得溶液中原料的含有量/相应的原料用量,计算得到的。对实施例1~6制备的一种动物用复方氨基酸溶液N1~N6的外观和含量进行测定,具体结果见表2:
表2实施例1~6中制得的一种动物用复方氨基酸溶液质量检测结果一览表
由表2可知,实施例1~6制备的一种动物用复方氨基酸溶液N1~N6颜色呈无色澄清,氨基酸与维生素的含量均符合标准,且其他检查相关项均已全部合格。
实施例8一种动物用复方氨基酸溶液的稳定性检测
对实施例1~6制备的一种动物用复方氨基酸溶液N1~N6进行质量检测,具体检测方法如下:
加速试验在温度40±2℃、相对湿度75±5%的条件下放置6个月,在试验期间第0个月、1个月、2个月、3个月、6个月末分别取样,按《国家食品药品监督管理局药品标准》WS1~(X~324)~2003Z的质量标准进行检测,氨基酸和维生素相应的标示量应控制在90.0~110.0%,标示量计算是根据所得溶液中原料的含有量/相应的原料用量,计算得到的,具体检测结果见表3~8:
表3一种动物用复方氨基酸溶液N1质量检测结果
表4一种动物用复方氨基酸溶液N2质量检测结果
表5一种动物用复方氨基酸溶液N3质量检测结果
表6一种动物用复方氨基酸溶液N4质量检测结果
表7一种动物用复方氨基酸溶液N5质量检测结果
表8一种动物用复方氨基酸溶液N6质量检测结果
由表3~8可知,实施例1~6制备的一种动物用复方氨基酸溶液N1~N6经过加速试验,各指标均无明显变化,质量稳定性良好,因此,本发明的制备的一种动物用复方氨基酸溶液具有很好的稳定性。
实施例9一种动物用复方氨基酸溶液的应用
一)一种动物用复方氨基酸溶液对蛋鸡的B族维生素缺乏症的改善效果实验
鸡的氨基酸和B族维生素缺乏症常突然发生,表现为厌食、消瘦、贫血、体温降低、腿软无力,有的甚至出现腹泻,继而引发多发性神经炎,腿、翅、颈出现伸肌痉挛,病鸡以飞节和尾部着地,仿佛坐于地面,头向后仰,呈特征性的“观星”姿势,有时倒地侧卧,头仍向后仰,严重时衰竭死亡。成年鸡发病较慢,除精神、食欲失常外,还表现出鸡冠呈蓝紫色、步态不稳、进行性瘫痪等症状。
剖检病死鸡,可见皮肤广泛水肿;肾上腺明显肥大,胃肠有炎症,十二指肠溃疡;心脏右侧常出现扩张,心房较心室明显;生殖器官萎缩,尤其是公鸡的睾丸较为明显。
本次试验在出现B族维生素缺乏症的石家庄某大型鸡场进行,鸡群出现食欲不振、消瘦、跛行、体重减少等症状,结合临床症状与维生素检测,经当地兽医确诊,患有B族维生素缺乏症。选取700只300日龄具有B族维生素缺乏症的海兰灰蛋鸡,随机分成7组,每组100只,分别为对照组和JA1~JA6组,其中,对照组给予预混了0.5‰液态维生素的饮水,JA1~JA6组一一对应给予预混了0.5‰一种动物用复方氨基酸注射液N1~N6的饮水,全天不限量供应,连续试验20天,并给予正常饲喂。
试验采用三层立体笼养,饲喂对应饲料,自由采食与饮水。按照海兰灰蛋鸡常规免疫程序免疫和饲养管理,每日进行鸡舍消毒,保证鸡舍卫生。试验期间每天观察蛋鸡的增重和产蛋情况,并进行统计,具体结果见下表:
表9一种动物用复方氨基酸溶液对蛋鸡B族缺乏症的应用效果一览表
由表9可知,JA1~JA6组和对照组鸡群体重减少症状消失,产蛋率和平均蛋重均有所提高,料蛋比和破蛋率均有所降低,但JA1~JA6组的体重的平均增长值比对照组提高0.008kg以上,JA1~JA6组的死亡率比对照组降低9%以上,JA1~JA6组的产蛋率比对照组提高13%以上,JA1~JA6组的平均蛋重比对照组增加3g/个以上,JA1~JA6组的料蛋比比对照组降低0.1%以上,JA1~JA6组的破蛋率比对照组降低0.9%以上。以上实验结果证明本发明制备的一种动物用复方氨基酸溶液对于蛋鸡的B族维生素缺乏症具有很好的改善作用。
二)一种动物用复方氨基酸溶液促进病奶牛生长发育的效果实验
本次试验在某大型奶牛养殖场进行,奶牛出现厌食、消瘦、全身无力、产奶量减少等症状,结合临床症状,经当地兽医确诊,患有氨基酸缺乏症。选取28只中国荷斯坦奶牛,随机分成7组,每组4只,分别为对照组和NA1~NA6组,其中,对照组给予预混了1‰口服葡萄糖溶液的饮水,NA1~NA6组一一对应给予预混了1‰一种动物用复方氨基酸注射液N1~N6的饮水,全天不限量供应,连续试验7天,并给予正常饲喂。试验期间每天观察奶牛的增重和产奶情况,并进行统计,具体结果见下表:
表10一种动物用复方氨基酸溶液对奶牛氨基酸缺乏症的应用效果一览表
组别 | 对照组 | NA1组 | NA2组 | NA3组 | NA4组 | NA5组 | NA6组 |
奶牛数(头) | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
20天后体重的平均增长值(kg) | 0.30 | 1.56 | 1.32 | 1.20 | 1.15 | 1.26 | 1.37 |
开始时平均采食量(kg/d) | 18.5 | 18.0 | 18.3 | 18.2 | 18.6 | 18.4 | 18.6 |
20天后平均采食量(kg/d) | 18.6 | 21.2 | 20.7 | 20.9 | 21.1 | 21.0 | 20.8 |
开始时平均产奶量(kg/d) | 16.8 | 16.7 | 16.9 | 16.5 | 16.5 | 16.6 | 16.8 |
20天后平均产奶量(kg/d) | 16.7 | 22.1 | 21.2 | 21.5 | 21.6 | 21.9 | 21.3 |
开始时牛奶中乳脂含量(%) | 3.0 | 2.9 | 3.1 | 3.0 | 2.8 | 3.2 | 3.1 |
20天后牛奶中乳脂含量(%) | 3.1 | 3.68 | 3.55 | 3.62 | 3.58 | 3.64 | 3.63 |
开始时牛奶中乳蛋白含量(%) | 3.0 | 2.9 | 3.0 | 3.1 | 2.9 | 3.0 | 2.9 |
20天后牛奶中乳蛋白含量(%) | 2.9 | 3.2 | 3.3 | 3.3 | 3.4 | 3.4 | 3.3 |
开始时牛奶中乳糖含量(%) | 3.92 | 3.93 | 3.92 | 3.95 | 3.91 | 3.94 | 3.92 |
20天后牛奶中乳糖含量(%) | 3.95 | 4.76 | 4.56 | 4.70 | 4.67 | 4.63 | 4.59 |
由表10可知,NA1~NA6组的体重的平均增长值比对照组提高0.85kg以上,NA1~NA6组的平均采食量比对照组提高2.3kg/d以上,NA1~NA6组的产奶量比对照组提高4.4kg/d以上,NA1~NA6组的牛奶中乳脂含量比对照组提高0.43%以上,NA1~NA6组的牛奶中乳蛋白含量比对照组提高0.3%以上,NA1~NA6组的牛奶中乳糖含量比对照组提高0.61%以上。以上实验结果证明本发明制备的一种动物用复方氨基酸溶液对于奶牛的氨基酸缺乏症具有很好的改善作用。
Claims (10)
1.一种动物用复方氨基酸溶液,其特征在于,制成每1000体积份所述动物用复方氨基酸溶液的有效成分的原料,以重量份数计包括:
①由盐酸精氨酸0.80~10.00份、盐酸组氨酸0.60~6.50份、亮氨酸2.00~16.00份、异亮氨酸0.40~14.00份、赖氨酸0.90~13.00份、苯丙氨酸1.00~16.50份、苏氨酸0.60~6.80份、缬氨酸0.40~12.90份和甘氨酸0.90~20.00份组成的组合氨基酸;
②色氨酸0.18~4.80份;
③由维生素B1 1.00~4.00份、维生素B2 2.00~8.00份、维生素B3 10.00~30.00份和维生素B6 2.00~10.00份组成的B族维生素;
④由抗氧剂0.50~1.00份、络合剂0.10~0.30份和防腐剂2.00~10.00份组成的辅料;
⑤余量为水;
其中,重量份数与体积份数的比例关系为1kg:1L。
2.根据权利要求1所述的一种动物用复方氨基酸溶液,其特征在于,所述抗氧剂为亚硫酸氢钠、硫脲或焦亚硫酸钠。
3.根据权利要求1或2所述的一种动物用复方氨基酸溶液,其特征在于,所述络合剂为乙二胺四乙酸二钠、酒石酸或柠檬酸。
4.根据权利要求1或2所述的一种动物用复方氨基酸溶液,其特征在于,所述防腐剂为苯甲酸钠、尼泊金乙酯钠或尼泊金丙酯钠。
5.权利要求1-4中任一项所述的一种动物用复方氨基酸溶液的制备方法,其特征在于,该制备方法包括依次进行的以下步骤:
1)取辅料加至足够量的水中,80~100℃充分溶解后,再加入组合氨基酸和B族维生素,80~100℃充分溶解,得溶液X;
2)溶液X中加入色氨酸,在70℃以下充分溶解后,调节pH值,用水定容,过滤,即得所述一种动物用复方氨基酸溶液。
6.根据权利要求5所述的一种动物用复方氨基酸溶液的制备方法,其特征在于,步骤2)中,调节pH值至4.2~6.8。
7.根据权利要求5或6所述的一种动物用复方氨基酸溶液的制备方法,其特征在于,所述过滤分为粗滤和精滤。
8.根据权利要求7所述的一种动物用复方氨基酸溶液的制备方法,其特征在于,所述精滤是利用微孔滤膜进行过滤除菌。
9.权利要求1-4中任一项所述的一种动物用复方氨基酸溶液的应用,其特征在于,所述一种动物用复方氨基酸溶液用于改善动物机体营养缺失。
10.根据权利要求9所述的一种动物用复方氨基酸溶液的应用,其特征在于,所述一种动物用复方氨基酸溶液添加至饮水中,用于饲喂动物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010905082.XA CN114099516A (zh) | 2020-09-01 | 2020-09-01 | 一种动物用复方氨基酸溶液及其制备方法和应用 |
PCT/CN2020/116378 WO2022047840A1 (zh) | 2020-09-01 | 2020-09-21 | 一种动物用复方氨基酸溶液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010905082.XA CN114099516A (zh) | 2020-09-01 | 2020-09-01 | 一种动物用复方氨基酸溶液及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114099516A true CN114099516A (zh) | 2022-03-01 |
Family
ID=80360396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010905082.XA Pending CN114099516A (zh) | 2020-09-01 | 2020-09-01 | 一种动物用复方氨基酸溶液及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114099516A (zh) |
WO (1) | WO2022047840A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1781486A (zh) * | 2004-11-30 | 2006-06-07 | 南京圣和药业有限公司 | 一种复方氨基酸与维生素胶囊制剂及其制备方法 |
CN1823766A (zh) * | 2006-03-30 | 2006-08-30 | 胡正岳 | 一种复方氨基酸维生素分散片及其制备方法 |
US20060246173A1 (en) * | 2005-04-28 | 2006-11-02 | Raffo Mewafak K | Feed compositions and methods of making and using the same |
CN103053807A (zh) * | 2013-01-24 | 2013-04-24 | 南京日升昌生物技术有限公司 | 一种水溶性复合维生素制剂及其制备方法 |
CN104509919A (zh) * | 2013-09-30 | 2015-04-15 | 张自力 | 一种功能性营养素饮料 |
CN105708829A (zh) * | 2016-01-21 | 2016-06-29 | 广东嘉博制药有限公司 | 一种复合维生素氨基酸口服液及其制备方法和应用 |
-
2020
- 2020-09-01 CN CN202010905082.XA patent/CN114099516A/zh active Pending
- 2020-09-21 WO PCT/CN2020/116378 patent/WO2022047840A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1781486A (zh) * | 2004-11-30 | 2006-06-07 | 南京圣和药业有限公司 | 一种复方氨基酸与维生素胶囊制剂及其制备方法 |
US20060246173A1 (en) * | 2005-04-28 | 2006-11-02 | Raffo Mewafak K | Feed compositions and methods of making and using the same |
CN1823766A (zh) * | 2006-03-30 | 2006-08-30 | 胡正岳 | 一种复方氨基酸维生素分散片及其制备方法 |
CN103053807A (zh) * | 2013-01-24 | 2013-04-24 | 南京日升昌生物技术有限公司 | 一种水溶性复合维生素制剂及其制备方法 |
CN104509919A (zh) * | 2013-09-30 | 2015-04-15 | 张自力 | 一种功能性营养素饮料 |
CN105708829A (zh) * | 2016-01-21 | 2016-06-29 | 广东嘉博制药有限公司 | 一种复合维生素氨基酸口服液及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2022047840A1 (zh) | 2022-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gorelik et al. | The state of nonspecific resistance of calves during the preweaning period. | |
CN105053217A (zh) | 一种婴幼儿配方羊奶粉及其制作方法 | |
Berends et al. | Effects of exchanging lactose for fat in milk replacer on ad libitum feed intake and growth performance in dairy calves | |
EP4212161A1 (en) | Sperm motility improving agent and sperm motility improving method | |
Tao et al. | Determination of intravenous non-protein energy and nitrogen requirements in growing rats | |
WO2021203606A1 (zh) | 畜用复方氨基酸注射液的制备方法 | |
AU2016373862A1 (en) | Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate | |
CN111919889A (zh) | 一种提高免疫力的母乳化婴幼儿配方羊奶粉及其制备方法 | |
CN114099516A (zh) | 一种动物用复方氨基酸溶液及其制备方法和应用 | |
CN103053807B (zh) | 一种水溶性复合维生素制剂及其制备方法 | |
CN104222624A (zh) | 一种奶牛维生素预混料及其制备方法 | |
Dubeski et al. | Effects of B vitamin injections on plasma B vitamin concentrations of feed-restricted beef calves infected with bovine herpesvirus-1 | |
RU2652155C1 (ru) | Способ производства функционального кормового продукта для сельскохозяйственных животных | |
Vijayalakshmy et al. | The role of B Vitamins in livestock nutrition | |
Watford et al. | Optimal dietary glutamine for growth and development | |
CN103918902A (zh) | 一种断奶仔猪用液态补充饲料及该饲料的配制饲喂方法 | |
RU2425674C2 (ru) | Комплексный фармацевтический препарат | |
US20070042020A1 (en) | Composition for the treatment of dysfunctional energy metabolism syndrome | |
CN112841431A (zh) | 一种适合口服使用的奶牛酮病防治复合配方 | |
CN105995119A (zh) | 一种构建肝豆状核变性动物模型的高铜饲料及其制备方法 | |
CN113057971A (zh) | 枯草芽孢杆菌在制备改善牛瘤胃液药物中的应用 | |
Yaremchuk et al. | Prevention of hepatosis in laying hens using hepatoprotectors Hep-A-Stress and Hepasan-VS | |
Tkacheva | Physiological features of hematological parameters of sows during suckling, kept in the ecological conditions of central Russia | |
RU2520840C2 (ru) | Комплексный пробиотический препарат для крупного рогатого скота мясных пород | |
CN111820284A (zh) | 一种优化氨基酸模式和提高免疫力的婴幼儿配方奶粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220301 |